Immatics N.V. (IMTX)
$7.21-2.96%Close
SELLCRISIS · day 7
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $967M
- Beta
- 1.36
- P/E (TTM)
- -4.19
- Short % float
- 3.29%
- Days to cover
- 4.2
- SI change
- -16.8%
- 1W
- -6.73%
- 1M
- -17.97%
- vs SPY 1W
- -7.15%
- vs SPY 1M
- -20.04%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on IMTX?
- LOPJLB’s latest quantitative signal on Immatics N.V. (IMTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is IMTX in?
- Immatics N.V. (IMTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Immatics N.V. (IMTX) do?
- Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's A…